People with type 2 diabetes and cardiovascular disease receiving the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin (Jardiance) were less likely to die than those taking placebo according to a landmark trial reported at EASD in Stockholm last week. Published simultaneously in the NEJM the EMPA-REG OUTCOME study of over 7,000 people showed that while there were no significant ...
Type 2 diabetes
Type 2 diabetes drug cuts CV death
22 Sep 2015